Literature DB >> 12833064

Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells.

Yong-Hui Zheng1, Hai-Feng Yu, B Matija Peterlin.   

Abstract

In the mouse, replication of human immunodeficiency virus type 1 (HIV) is blocked at the levels of entry, transcription and assembly. For the latter effect, the amounts of unspliced viral genomic RNA could have an important function. Indeed, in murine cells, HIV transcripts are spliced excessively, a process that is not inhibited by the murine splicing inhibitor p32 (mp32). In marked contrast, its human counterpart, hp32, not only blocks this splicing but promotes the accumulation of viral genomic transcripts and structural proteins, resulting in the assembly and release of infectious virions. A single substitution in hp32 of Gly 35 to Asp 35, which is found in mp32, abrogates this activity. Thus, hp32 overcomes an important post-transcriptional block to HIV replication in murine cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833064     DOI: 10.1038/ncb1000

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  48 in total

1.  An acidic protein, YBAP1, mediates the release of YB-1 from mRNA and relieves the translational repression activity of YB-1.

Authors:  Ken Matsumoto; Kimio J Tanaka; Masafumi Tsujimoto
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

2.  Cellular splicing and transcription regulatory protein p32 represses adenovirus major late transcription and causes hyperphosphorylation of RNA polymerase II.

Authors:  Christina Ohrmalm; Göran Akusjärvi
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  New way of regulating alternative splicing in retroviruses: the promoter makes a difference.

Authors:  Jens Bohne; Axel Schambach; Daniela Zychlinski
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate.

Authors:  Jinglin Sun; Timothy Soos; Vineet N Kewalramani; Kristin Osiecki; Jian Hua Zheng; Laurie Falkin; Laura Santambrogio; Dan R Littman; Harris Goldstein
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 5.  Insights into the nuclear export of murine leukemia virus intron-containing RNA.

Authors:  Lucie Pessel-Vivares; Laurent Houzet; Sébastien Lainé; Marylène Mougel
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

6.  Matrix-induced inhibition of membrane binding contributes to human immunodeficiency virus type 1 particle assembly defects in murine cells.

Authors:  Theodora Hatziioannou; Juan Martin-Serrano; Trinity Zang; Paul D Bieniasz
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Nuclear import of the preintegration complex is blocked upon infection by human immunodeficiency virus type 1 in mouse cells.

Authors:  Naomi Tsurutani; Jiro Yasuda; Naoki Yamamoto; Byung-Il Choi; Motohiko Kadoki; Yoichiro Iwakura
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32.

Authors:  Reem Berro; Kylene Kehn; Cynthia de la Fuente; Anne Pumfery; Richard Adair; John Wade; Anamaris M Colberg-Poley; John Hiscott; Fatah Kashanchi
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag.

Authors:  Kristen A Porter; Lauren N Kelley; Annette George; Jonathan A Harton; Karen M Duus
Journal:  PLoS One       Date:  2010-06-24       Impact factor: 3.240

10.  Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Authors:  Mainul Hoque; Hartmut M Hanauske-Abel; Paul Palumbo; Deepti Saxena; Darlene D'Alliessi Gandolfi; Myung Hee Park; Tsafi Pe'ery; Michael B Mathews
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.